{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:18:45Z","timestamp":1760242725816,"version":"3.37.3"},"reference-count":51,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2015,4,14]],"date-time":"2015-04-14T00:00:00Z","timestamp":1428969600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tissue Antigens"],"published-print":{"date-parts":[[2015,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Downregulation of major histocompatibility complex class I chain\u2010related molecule A (<jats:styled-content style=\"fixed-case\">MICA<\/jats:styled-content>) and upregulation of human leukocyte antigen G (<jats:styled-content style=\"fixed-case\">HLA<\/jats:styled-content>\u2010G) on the tumor cells are important immune escape mechanisms for different epithelial tumors. In addition, upregulation of the soluble forms of the latter molecules in serum leads to peripheral T\u2010cell and natural killer (<jats:styled-content style=\"fixed-case\">NK<\/jats:styled-content>)\u2010cell tolerance. As for cervical cancer, it remains unknown whether soluble <jats:styled-content style=\"fixed-case\">MICA<\/jats:styled-content> (<jats:styled-content style=\"fixed-case\">sMICA<\/jats:styled-content>) and soluble <jats:styled-content style=\"fixed-case\">HLA<\/jats:styled-content>\u2010G (<jats:styled-content style=\"fixed-case\">sHLA<\/jats:styled-content>\u2010G) concentrations are related to tumor characteristics or patient survival rates. We measured <jats:styled-content style=\"fixed-case\">sMICA<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">sHLA<\/jats:styled-content>\u2010G in pre\u2010treatment sera of a large cohort of cervical cancer patients (<jats:italic>n<\/jats:italic>\u2009=\u2009366) by enzyme\u2010linked immunosorbent assay (<jats:styled-content style=\"fixed-case\">ELISA<\/jats:styled-content>). We detected a median <jats:styled-content style=\"fixed-case\">sMICA<\/jats:styled-content> of 174.73\u2009pg\/ml and a median <jats:styled-content style=\"fixed-case\">sHLA<\/jats:styled-content>\u2010G of 5.35\u2009U\/ml. We did not find an association between <jats:styled-content style=\"fixed-case\">sHLA<\/jats:styled-content>\u2010G levels and clinicopathological characteristics. In adenocarcinoma, low <jats:styled-content style=\"fixed-case\">sMICA<\/jats:styled-content> concentration was positively related to recurrent disease, a higher International Federation of Gynecology and Obstetrics (<jats:styled-content style=\"fixed-case\">FIGO<\/jats:styled-content>) stage and vaginal involvement (Mann\u2013Whitney <jats:italic>U<\/jats:italic>\u2010test; <jats:italic>P<\/jats:italic>\u2009=\u20090.018, <jats:italic>P<\/jats:italic>\u2009=\u20090.042 and <jats:italic>P<\/jats:italic>\u2009=\u20090.013, respectively). In the latter patient group, high <jats:styled-content style=\"fixed-case\">sMICA<\/jats:styled-content> levels were associated with better disease\u2010free survival (<jats:styled-content style=\"fixed-case\">DFS<\/jats:styled-content>) and disease\u2010specific survival (<jats:styled-content style=\"fixed-case\">DSS<\/jats:styled-content>) (<jats:italic>P<\/jats:italic>\u2009=\u20090.011 and <jats:italic>P<\/jats:italic>\u2009=\u20090.047). After adjusting for confounding factors, high <jats:styled-content style=\"fixed-case\">sMICA<\/jats:styled-content> proved to be an independent predictor for a better <jats:styled-content style=\"fixed-case\">DFS<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">DSS<\/jats:styled-content> [<jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content> 0.16; 95% confidence interval (<jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>) 0.04\u20130.64; <jats:italic>P<\/jats:italic>\u2009=\u20090.009 and <jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content> 0.12; 95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content> 0.03\u20130.50; <jats:italic>P<\/jats:italic>\u2009=\u20090.004]. <jats:styled-content style=\"fixed-case\">sHLA<\/jats:styled-content>\u2010G did not influence survival in cervical cancer patients, regardless of histology. We conclude that cervical adenocarcinoma patients with high <jats:styled-content style=\"fixed-case\">sMICA<\/jats:styled-content> levels have an increased DFS and DSS. This data warrants a prospective trial to study the functional role of <jats:styled-content style=\"fixed-case\">sMICA<\/jats:styled-content> in cervical adenocarcinoma.\n<\/jats:p>","DOI":"10.1111\/tan.12562","type":"journal-article","created":{"date-parts":[[2015,4,14]],"date-time":"2015-04-14T10:52:53Z","timestamp":1429008773000},"page":"476-483","source":"Crossref","is-referenced-by-count":18,"title":["High levels of soluble <scp>MICA<\/scp> are significantly related to increased disease\u2010free and disease\u2010specific survival in patients with cervical adenocarcinoma"],"prefix":"10.1111","volume":"85","author":[{"given":"S.","family":"Samuels","sequence":"first","affiliation":[{"name":"Department of Gynecology Netherlands Cancer Institute\u00a0\u2013\u00a0Antoni van Leeuwenhoek (in collaboratation within the Centre for Gynecologic Oncology Amsterdam (CGOA))  Amsterdam the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. M.","family":"Ferns","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology VU University Medical Center (in collaboratation within the Centre for Gynecologic Oncology Amsterdam (CGOA))  Amsterdam the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Meijer","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology Amsterdam Medical Center (in collaboratation within the Centre for Gynecologic Oncology Amsterdam (CGOA))  Amsterdam the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. P.","family":"van Straalen","sequence":"additional","affiliation":[{"name":"Department of Clinical Chemistry Amsterdam Medical Center  Amsterdam the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. R.","family":"Buist","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology Amsterdam Medical Center (in collaboratation within the Centre for Gynecologic Oncology Amsterdam (CGOA))  Amsterdam the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. J.","family":"Zijlmans","sequence":"additional","affiliation":[{"name":"Department of Gynecology Netherlands Cancer Institute\u00a0\u2013\u00a0Antoni van Leeuwenhoek (in collaboratation within the Centre for Gynecologic Oncology Amsterdam (CGOA))  Amsterdam the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. G.","family":"Kenter","sequence":"additional","affiliation":[{"name":"Department of Gynecology Netherlands Cancer Institute\u00a0\u2013\u00a0Antoni van Leeuwenhoek (in collaboratation within the Centre for Gynecologic Oncology Amsterdam (CGOA))  Amsterdam the Netherlands"},{"name":"Department of Obstetrics and Gynecology VU University Medical Center (in collaboratation within the Centre for Gynecologic Oncology Amsterdam (CGOA))  Amsterdam the Netherlands"},{"name":"Department of Obstetrics and Gynecology Amsterdam Medical Center (in collaboratation within the Centre for Gynecologic Oncology Amsterdam (CGOA))  Amsterdam the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. S.","family":"Jordanova","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology VU University Medical Center (in collaboratation within the Centre for Gynecologic Oncology Amsterdam (CGOA))  Amsterdam the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,4,14]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"FerlayJ SoerjomataramI ErvikM et al. GLOBOCAN 2012 v1.0 Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [internet]. 2013.http:\/\/globocan.iarc.fr."},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.55.4.244"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/171.4.1026"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-9966-30-12"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-2704"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21382"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-8-16"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-010-9480-9"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-006-0167-1"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200422206"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.8.4098"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4554"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2011.01989.x"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature01112"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni858"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/2051-1426-1-S1-P41"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0097"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2007.07.004"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1044-579X(03)00028-2"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0039.2010.01607.x"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190802129934"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25372"},{"key":"e_1_2_7_25_1","first-page":"1021","article-title":"Soluble human leukocyte antigen\u2010G expression in patients with ductal and lobular breast malignancy","volume":"32","author":"Provatopoulou X","year":"2012","journal-title":"Anticancer Res"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2010.02.015"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgo.2009.02.009"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.4161\/onci.26491"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.4383"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0463"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25807"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2012.07.041"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1159\/000334089"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0044743"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2008.01.010"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12072"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28174"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0069044"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21510"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0023348"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2010.100323"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(00)00376-2"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djj067"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600688"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-014-0255-5"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28288"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-10-184"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/tan.12478"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1089\/jwh.2011.3385"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20000915)89:6<1291::AID-CNCR14>3.0.CO;2-O"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-015-0440-6"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-014-0416-y"}],"container-title":["Tissue Antigens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftan.12562","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tan.12562","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T15:11:28Z","timestamp":1696173088000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tan.12562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,14]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["10.1111\/tan.12562"],"URL":"https:\/\/doi.org\/10.1111\/tan.12562","archive":["Portico"],"relation":{},"ISSN":["0001-2815","1399-0039"],"issn-type":[{"type":"print","value":"0001-2815"},{"type":"electronic","value":"1399-0039"}],"subject":[],"published":{"date-parts":[[2015,4,14]]}}}